Transfusion‐associated circulatory overload—a systematic review of diagnostic biomarkers
暂无分享,去创建一个
M. Murphy | Michael F Murphy | A. Vlaar | D. Veelo | Bart F Geerts | Robert B Klanderman | Joachim J Bosboom | Yazan Migdady | Denise P Veelo | Alexander P J Vlaar | B. Geerts | Y. Migdady | J. Bosboom | R. B. Klanderman
[1] L. Sokoll,et al. N‐terminal pro‐brain natriuretic peptide is a useful diagnostic marker for transfusion‐associated circulatory overload , 2008, Transfusion.
[2] D. Lloyd‐Jones,et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.
[3] E. Ruokonen,et al. Predictive value of N-terminal pro–brain natriuretic peptide in severe sepsis and septic shock* , 2007, Critical care medicine.
[4] S. Fu,et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure , 2018, Journal of Biological Engineering.
[5] M. Popovsky,et al. How we view and approach transfusion‐associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention , 2013, Transfusion.
[6] T. Mueller,et al. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. , 2003, Clinical chemistry.
[7] Antoni Bayes-Genis,et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.
[8] J. Steingrub,et al. Hemotherapy bedside biovigilance involving vital sign values and characteristics of patients with suspected transfusion reactions associated with fluid challenges: can some cases of transfusion‐associated circulatory overload have proinflammatory aspects? , 2012, Transfusion.
[9] S. Kleinman,et al. Incidence and clinical characteristics of transfusion‐associated circulatory overload using an active surveillance algorithm , 2017, Vox sanguinis.
[10] J. Callum,et al. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. , 2013, Transfusion medicine reviews.
[11] J. Callum,et al. The association of fever with transfusion‐associated circulatory overload , 2017, Vox sanguinis.
[12] C. Silliman,et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. , 2003, Blood.
[13] M. Looney,et al. Transfusion‐related acute lung injury in the paediatric patient: two case reports and a review of the literature , 2006, Transfusion medicine.
[14] O. Gajic,et al. Pulmonary edema after transfusion: How to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury , 2006, Critical care medicine.
[15] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[16] Elizabeth Sykes,et al. Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP. , 2005, American journal of clinical pathology.
[17] S. Réhman,et al. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. , 2008, Journal of the American College of Cardiology.
[18] C. Lindsell,et al. Galectin 3 complements BNP in risk stratification in acute heart failure , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[19] M. Tomaniak,et al. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience. , 2016, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[20] Fred S Apple,et al. Third universal definition of myocardial infarction , 2012 .
[21] E. Shapiro,et al. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit , 2005 .
[22] O. Gajic,et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N‐terminal pro‐brain natriuretic) in the differentiation between transfusion‐related acute lung injury and transfusion‐related circulatory overload in the critically ill , 2009, Transfusion.
[23] A. Wu,et al. Transfusion‐related acute lung injury and transfusion‐associated circulatory overload: mutually exclusive or coexisting entities? , 2007, Transfusion.
[24] J. Binnekade,et al. The practice of diagnosing and reporting transfusion‐associated circulatory overload: a national survey among physicians and haemovigilance officers , 2018, Transfusion medicine.
[25] M. Shlipak,et al. Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2006, Circulation.
[26] E. Murphy,et al. Transfusion-associated circulatory overload (TACO): prevention, management, and patient outcomes , 2015 .
[27] G. Hillis,et al. B‐Type natriuretic peptide and the prediction of outcome in patients admitted to intensive care , 2005, Anaesthesia.
[28] E. Murphy,et al. Differentiating pulmonary transfusion reactions using recipient and transfusion factors , 2017, Transfusion.
[29] F. Maupas-Schwalm,et al. Head-to-head comparison of 10 natriuretic peptide assays , 2015, Clinical chemistry and laboratory medicine.
[30] J. Raval,et al. Passive reporting greatly underestimates the rate of transfusion‐associated circulatory overload after platelet transfusion , 2015, Vox sanguinis.
[31] N. Juffermans,et al. Transfusion-related acute lung injury: a clinical review , 2013, The Lancet.
[32] R. Skeate,et al. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload , 2007, Current opinion in hematology.
[33] E. Massey,et al. Guideline on the investigation and management of acute transfusion reactions Prepared by the BCSH Blood Transfusion Task Force , 2012, British journal of haematology.
[34] M. Alpert,et al. Short-term fluctuations of plasma NT-proBNP levels in patients with new-onset atrial fibrillation: a way to assess time of onset? , 2010, Heart.
[35] A. Maisel,et al. Role of Cardiac Troponin Levels in Acute Heart Failure. , 2015, Cardiac failure review.
[36] E. Murphy,et al. Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions , 2015, Transfusion.
[37] Anan Huang,et al. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction , 2018, Acta cardiologica.
[38] A. Maisel,et al. Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure , 2016, Arquivos brasileiros de cardiologia.
[39] C. Passino,et al. Systematic differences between BNP immunoassays: comparison of methods using standard protocols and quality control materials. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[40] Y. Kihara,et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.
[41] P. Ponikowski,et al. Growth differentiation factor 15 (GDF‐15) in patients admitted for acute heart failure: results from the RELAX‐AHF study , 2015, European journal of heart failure.
[42] M. Matthay,et al. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.
[43] M. Looney,et al. Reducing Noninfectious Risks of Blood Transfusion , 2011, Anesthesiology.
[44] L. Lenert,et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.
[45] D. Talmor,et al. Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. , 2007, Chest.
[46] U. Sachs,et al. Pulmonary Transfusion Reactions , 2008, Transfusion Medicine and Hemotherapy.
[47] W. Seeger,et al. Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. , 1996, The European respiratory journal.
[48] M. Levi,et al. Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: A prospective nested case-control study* , 2012, Critical care medicine.
[49] D. Giacherio,et al. Use of B‐natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion‐associated circulatory overload , 2005, Transfusion.
[50] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[51] Analytical Relationships Among Biosite, Bayer, and Roche Methods for BNP and NT-proBNP , 2005 .
[52] O. Hammarsten,et al. Prognostic values of NTpro BNP/BNP ratio in comparison with NTpro BNP or BNP alone in elderly patients with chronic heart failure in a 2-year follow up. , 2012, International journal of cardiology.
[53] C. Camargo,et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.
[54] E. Zwang,et al. Vitamin K‐dependent coagulation factors and fibrinogen levels in FFP remain stable upon repeated freezing and thawing , 2003, Transfusion.
[55] Claudio Passino,et al. State of the art of immunoassay methods for B-type natriuretic peptides: An update , 2015, Critical reviews in clinical laboratory sciences.
[56] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.
[57] H. Nakazawa,et al. Impact of immunoreactive substances contained in apheresis platelet concentrate on postoperative respiratory function in surgical patients receiving platelet transfusion: a prospective cohort study , 2013, Transfusion medicine.